Time and Venue: 2–4 April 2020; Munich, Germany
About: The 7th Immunotherapy of Cancer Conference (ITOC7) to be held in Munich, Germany from April 2 – 4, 2020 is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.
ITOC7 is organized by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TZM), the Society for Immunotherapy of Cancer (SITC), the German Cancer Consortium (DKTK) as well as the Comprehensive Cancer Center Munich (CCCM) in Munich.
The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.
Time and Venue: 15th - 17th June 2020; University of Kent, Canterbury, UK
About: Despite substantial improvements in recent decades, the prognosis for those cancer patients who suffer from metastatic diseases and depend on systemic drug therapy remains unsatisfactorily poor. Both intrinsic resistance and the formation of acquired drug resistance substantially affect the efficacy of cancer drugs. The advancement of precision therapy, in particular the development of improved methods of analysing liquid biopsies, holds promise for improved monitoring of tumour response and the effective guidance of therapies to patients that will respond to it. The effective use of liquid biopsies will largely depend on the effective interpretation of ‘omics’ data. Moreover, functional data from pre-clinical resistance models will be needed to complement clinical data.
Hence, a close and intense collaboration is required between pre-clinical researchers, clinicians, and computational biologists to develop more effective anti-cancer therapies. This conference will bring together and showcase cancer researchers from these areas, who will present and discuss the latest advances in understanding the mechanisms of drug resistance in cancer, the identification of biomarkers of drug sensitivity/resistance and how they can be linked to precision medicine approaches.